董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Linda Marban | 女 | President, Chief Executive Officer and Director | 53 | 23.29万美元 | 未持股 | 2017-04-21 |
| David B. Musket | 男 | Director | 59 | 9.29万美元 | 未持股 | 2017-04-21 |
| Louis Manzo | 男 | Director | 79 | 6.00万美元 | 未持股 | 2017-04-21 |
| George W. Dunbar, Jr. | 男 | Director | 70 | 6.00万美元 | 未持股 | 2017-04-21 |
| Earl M. Collier, Jr. | 男 | Director | 69 | 4.88万美元 | 未持股 | 2017-04-21 |
| Joshua A. Kazam | 男 | Director | 40 | 3.00万美元 | 未持股 | 2017-04-21 |
| Frank Litvack | 男 | Executive Chairman and Director | 61 | 19.88万美元 | 未持股 | 2017-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Linda Marban | 女 | President, Chief Executive Officer and Director | 53 | 23.29万美元 | 未持股 | 2017-04-21 |
| Anthony Bergmann | 男 | Vice President of Finance and Principal Accounting Officer | 31 | 未披露 | 未持股 | 2017-04-21 |
| Karen G. Krasney | 女 | Executive Vice President and General Counsel | 64 | 37.39万美元 | 未持股 | 2017-04-21 |
| Rachel Smith | 女 | Vice President of Research and Development | 38 | 未披露 | 未持股 | 2017-04-21 |
| Leland Gershel | 男 | Chief Financial Officer and Principal Financial Officer | 45 | 47.72万美元 | 未持股 | 2017-04-21 |
| Deborah Ascheim | 女 | Chief Medical Officer | 52 | 51.51万美元 | 未持股 | 2017-04-21 |
董事简历
中英对照 | 中文 | 英文- Linda Marban
-
Linda Marban，博士，目前担任Capricor Therapeutics, Inc.的全资子公司Capricor, Inc首席执行官。她于2005年联合创立Capricor, Inc，并于2010年成为首席执行官。她将她的商业经验与研究背景结合起来领导Capricor，为其心脏治疗新疗法创造一个商业化路径。她是Capricor的基础即知识产权组合许可协议谈判的首席代表。在她担任首席执行官期间，Capricor, Inc担保美元的非稀释赠款和贷款奖励达到将近2700万美元，这些赠款和贷款奖励用来支持公司的研发项目和包括cap-1002产品在内的临床试验。她丰富的心脏空间知识，特别让她为公司的发展和成长提供独特的方向。从2003年到2009年，Marban 博士在Excigen，Inc.（一家生物技术初创公司）工作，负责业务开发、操作和临床前研究，并监督与Genzyme Corp达成的联合开发协议中基因治疗产品的开发。在Excigen工作期间，她也与Medtronic Corp.达成了共同开发与代理从属经营许可，利用Excigen的技术并监督执行此项任务的实验室的建立。她的职业生涯开始于学术科学研究，首先在克利夫兰医学中心工作，研究心肌的生物物理特性。当她搬到了约翰霍普金斯大学后这项工作继续进行。在约翰霍普金斯大学，她晋升为儿科研究助理教授级别，继续她对心衰收缩功能障碍的机制的研究。她在霍普金斯大学的任期从2000年持续到了2003年。Marban博士从凯斯西储大学获得了心脏生理学博士学位。
Linda Marban, Ph.D. is currently serving as Capricor Therapeutics, Inc.'s Chief Executive Officer. Co-founder of Capricor, Inc., Capricor Therapeutics, Inc.'s wholly-owned subsidiary, Dr. Marbán has been with Capricor, Inc. since 2005 and became its Chief Executive Officer in 2010. Dr. Marbán was the lead negotiator in procuring the license agreements that are the foundation of Capricor, Inc.'s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor, Inc. secured over $30.0 million in non-dilutive grants and a loan award which funds Capricor, Inc.'s research and development programs and clinical trials involving its CAP-1002 product. Dr. Marbán's deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company's development and growth. From 2003 to 2009 Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen's technology and supervised the building of a lab in which the work was to be performed. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University "JHU". While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology. - Linda Marban，博士，目前担任Capricor Therapeutics, Inc.的全资子公司Capricor, Inc首席执行官。她于2005年联合创立Capricor, Inc，并于2010年成为首席执行官。她将她的商业经验与研究背景结合起来领导Capricor，为其心脏治疗新疗法创造一个商业化路径。她是Capricor的基础即知识产权组合许可协议谈判的首席代表。在她担任首席执行官期间，Capricor, Inc担保美元的非稀释赠款和贷款奖励达到将近2700万美元，这些赠款和贷款奖励用来支持公司的研发项目和包括cap-1002产品在内的临床试验。她丰富的心脏空间知识，特别让她为公司的发展和成长提供独特的方向。从2003年到2009年，Marban 博士在Excigen，Inc.（一家生物技术初创公司）工作，负责业务开发、操作和临床前研究，并监督与Genzyme Corp达成的联合开发协议中基因治疗产品的开发。在Excigen工作期间，她也与Medtronic Corp.达成了共同开发与代理从属经营许可，利用Excigen的技术并监督执行此项任务的实验室的建立。她的职业生涯开始于学术科学研究，首先在克利夫兰医学中心工作，研究心肌的生物物理特性。当她搬到了约翰霍普金斯大学后这项工作继续进行。在约翰霍普金斯大学，她晋升为儿科研究助理教授级别，继续她对心衰收缩功能障碍的机制的研究。她在霍普金斯大学的任期从2000年持续到了2003年。Marban博士从凯斯西储大学获得了心脏生理学博士学位。
- Linda Marban, Ph.D. is currently serving as Capricor Therapeutics, Inc.'s Chief Executive Officer. Co-founder of Capricor, Inc., Capricor Therapeutics, Inc.'s wholly-owned subsidiary, Dr. Marbán has been with Capricor, Inc. since 2005 and became its Chief Executive Officer in 2010. Dr. Marbán was the lead negotiator in procuring the license agreements that are the foundation of Capricor, Inc.'s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor, Inc. secured over $30.0 million in non-dilutive grants and a loan award which funds Capricor, Inc.'s research and development programs and clinical trials involving its CAP-1002 product. Dr. Marbán's deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company's development and growth. From 2003 to 2009 Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen's technology and supervised the building of a lab in which the work was to be performed. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University "JHU". While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.
- David B. Musket
-
David B. Musket，2012年加入Capricor, Inc成为董事会成员和公司的审计委员会和薪酬委员会成员。他具有丰富的战略金融经验，并且已经在制药和医疗器械行业工作30年以上。Musket先生作为Goldman Sachs & Co。的一个股票研究分析师开始了他的投资生涯，之后是在制药行业。1991年他创办了Musket Research Associates，一个专门投资新兴的医疗保健公司的风险银行公司。1996年他共同创立了ProMed Management，一个医疗保健为重点的投资伙伴。到现在他仍然积极参与这两个公司的工作。在他的整个职业生涯中，他曾在几家私人和公共企业的董事会任职，目前他是TherOx, Inc（一家医疗设备公司）董事长。从1999年到2007年，他是上市公司Conor MedSystems（一家医疗设备公司，在2007年以14亿美元被Johnson & Johnson收购）董事会成员。他持有波士顿学院生物学理学士和心理学学士学位。
David B. Musket joined the Capricor, Inc. Board of Directors in 2012 and is Chairman of the Company’s Audit Committee and a member of the Compensation Committee. Mr. Musket has vast experience in strategic finance and has been following developments in the pharmaceutical and medical device industries for over 30 years. Mr. Musket began his investment career as an equities research analyst at Goldman Sachs & Co. following the pharmaceutical industry. From 1991 through 2016 he served as President of Musket Research Associates, a registered broker/dealer focused exclusively on venture banking transactions for emerging healthcare companies. In 1996 he co-founded ProMed Management, a healthcare-focused investment management company which he continues to run today. He has served on the boards of several private and public companies throughout his career. From 1999 to 2007 Mr. Musket served on the board of directors of publicly-traded Conor MedSystems, Inc., a medical device company sold to Johnson & Johnson in 2007 for $1.4 billion. Mr. Musket holds a Bachelor of Arts degree in Biology and Psychology from Boston College. - David B. Musket，2012年加入Capricor, Inc成为董事会成员和公司的审计委员会和薪酬委员会成员。他具有丰富的战略金融经验，并且已经在制药和医疗器械行业工作30年以上。Musket先生作为Goldman Sachs & Co。的一个股票研究分析师开始了他的投资生涯，之后是在制药行业。1991年他创办了Musket Research Associates，一个专门投资新兴的医疗保健公司的风险银行公司。1996年他共同创立了ProMed Management，一个医疗保健为重点的投资伙伴。到现在他仍然积极参与这两个公司的工作。在他的整个职业生涯中，他曾在几家私人和公共企业的董事会任职，目前他是TherOx, Inc（一家医疗设备公司）董事长。从1999年到2007年，他是上市公司Conor MedSystems（一家医疗设备公司，在2007年以14亿美元被Johnson & Johnson收购）董事会成员。他持有波士顿学院生物学理学士和心理学学士学位。
- David B. Musket joined the Capricor, Inc. Board of Directors in 2012 and is Chairman of the Company’s Audit Committee and a member of the Compensation Committee. Mr. Musket has vast experience in strategic finance and has been following developments in the pharmaceutical and medical device industries for over 30 years. Mr. Musket began his investment career as an equities research analyst at Goldman Sachs & Co. following the pharmaceutical industry. From 1991 through 2016 he served as President of Musket Research Associates, a registered broker/dealer focused exclusively on venture banking transactions for emerging healthcare companies. In 1996 he co-founded ProMed Management, a healthcare-focused investment management company which he continues to run today. He has served on the boards of several private and public companies throughout his career. From 1999 to 2007 Mr. Musket served on the board of directors of publicly-traded Conor MedSystems, Inc., a medical device company sold to Johnson & Johnson in 2007 for $1.4 billion. Mr. Musket holds a Bachelor of Arts degree in Biology and Psychology from Boston College.
- Louis Manzo
-
Louis Manzo，Capricor, Inc初始投资者之一，2006年加入Capricor, Inc董事会。他还是薪酬委员会成员、提名委员会成员及公司治理委员会成员。他是巴尔的摩著名企业家，拥有超过30年在金融领域的广泛经验。Manzo先生从圣母大学获得工商管理硕士学位，从哈佛商学院获得理学学士学位。他曾在美国海军军官担任军官。完成他在哈佛的学业后，Manzo先生加入Baker, Watts & Co（纽约证券交易所上市公司）并在几年后成为普通合伙人。他在该公司的经验包括了股权研究的董事和之后的企业财务主管。在1980年代，他创立了自己的私人投资公司LVM Venture Partners。1989年初，他成为创始人集团的一员，帮助了一位霍普金斯大学心脏病专家，帮助他落成预防心脏病研究中心。中心成立的前几年，他一直担任该中心顾问。他继续保持对预防研究的兴趣，包括一个主要的投资，以研究使用蛋白质建模的早期疾病检测。2002以来，他一直在支持成人干细胞在脊髓损伤修复中的应用研究。Manzo先生多年来在多家民营企业的董事会、公司高级顾问和慈善机构就职过，包括：霍普金斯大学的心脏病预防中心（一个中心医院）、大巴尔的摩医疗中心（医院）、Goodwill Industries of Maryland（一个非营利组织）、E.I.L. Instruments, Inc（一个仪器公司）以及马里兰州圣母大学（一所私立大学）。
Louis Manzo was one of the initial investors in Capricor, Inc. and joined the Capricor, Inc. Board of Directors in 2006. Mr. Manzo is also a member of the Company’s Compensation Committee and Nominating and Corporate Governance Committee. Mr. Manzo has been a prominent mid-Atlantic entrepreneur for over three decades and has extensive experience in the area of finance. Mr. Manzo received his Bachelor of Science degree from the University of Notre Dame and his M.B.A. from Harvard Business School. He served in the armed forces as an officer in the United States Navy. After completing his M.B.A. at Harvard, Mr. Manzo joined, and in a few years became General Partner of, Baker, Watts & Co., a New York Stock Exchange Member Firm. His experience there included being Director of Equity Research and, later, the Head of Corporate Finance. During the 1980’s, Mr. Manzo started his own private investment firm, LVM Venture Partners. Beginning in 1989 Mr. Manzo became part of the founders group which helped a Johns Hopkins cardiologist fund his launching of a research center for preventive cardiology. Mr. Manzo remained as an advisor during the center’s formative years. His continued interest in preventive research included a major investment to research the use of protein modeling for early disease detection. Since 2002 he has been following and supporting research into the use of adult stem cells in the repair of spinal cord and heart damage. The list of private company boards, senior advisory roles, and charities that Mr. Manzo has been involved with over the years are numerous and varied, including: the Johns Hopkins Preventive Cardiology Center, a hospital center; Greater Baltimore Medical Center, a hospital; Goodwill Industries of Maryland, a non-profit organization; E.I.L. Instruments, Inc., an instrument company; and University of Notre Dame, Advisory Council for Graduate Studies and Research. - Louis Manzo，Capricor, Inc初始投资者之一，2006年加入Capricor, Inc董事会。他还是薪酬委员会成员、提名委员会成员及公司治理委员会成员。他是巴尔的摩著名企业家，拥有超过30年在金融领域的广泛经验。Manzo先生从圣母大学获得工商管理硕士学位，从哈佛商学院获得理学学士学位。他曾在美国海军军官担任军官。完成他在哈佛的学业后，Manzo先生加入Baker, Watts & Co（纽约证券交易所上市公司）并在几年后成为普通合伙人。他在该公司的经验包括了股权研究的董事和之后的企业财务主管。在1980年代，他创立了自己的私人投资公司LVM Venture Partners。1989年初，他成为创始人集团的一员，帮助了一位霍普金斯大学心脏病专家，帮助他落成预防心脏病研究中心。中心成立的前几年，他一直担任该中心顾问。他继续保持对预防研究的兴趣，包括一个主要的投资，以研究使用蛋白质建模的早期疾病检测。2002以来，他一直在支持成人干细胞在脊髓损伤修复中的应用研究。Manzo先生多年来在多家民营企业的董事会、公司高级顾问和慈善机构就职过，包括：霍普金斯大学的心脏病预防中心（一个中心医院）、大巴尔的摩医疗中心（医院）、Goodwill Industries of Maryland（一个非营利组织）、E.I.L. Instruments, Inc（一个仪器公司）以及马里兰州圣母大学（一所私立大学）。
- Louis Manzo was one of the initial investors in Capricor, Inc. and joined the Capricor, Inc. Board of Directors in 2006. Mr. Manzo is also a member of the Company’s Compensation Committee and Nominating and Corporate Governance Committee. Mr. Manzo has been a prominent mid-Atlantic entrepreneur for over three decades and has extensive experience in the area of finance. Mr. Manzo received his Bachelor of Science degree from the University of Notre Dame and his M.B.A. from Harvard Business School. He served in the armed forces as an officer in the United States Navy. After completing his M.B.A. at Harvard, Mr. Manzo joined, and in a few years became General Partner of, Baker, Watts & Co., a New York Stock Exchange Member Firm. His experience there included being Director of Equity Research and, later, the Head of Corporate Finance. During the 1980’s, Mr. Manzo started his own private investment firm, LVM Venture Partners. Beginning in 1989 Mr. Manzo became part of the founders group which helped a Johns Hopkins cardiologist fund his launching of a research center for preventive cardiology. Mr. Manzo remained as an advisor during the center’s formative years. His continued interest in preventive research included a major investment to research the use of protein modeling for early disease detection. Since 2002 he has been following and supporting research into the use of adult stem cells in the repair of spinal cord and heart damage. The list of private company boards, senior advisory roles, and charities that Mr. Manzo has been involved with over the years are numerous and varied, including: the Johns Hopkins Preventive Cardiology Center, a hospital center; Greater Baltimore Medical Center, a hospital; Goodwill Industries of Maryland, a non-profit organization; E.I.L. Instruments, Inc., an instrument company; and University of Notre Dame, Advisory Council for Graduate Studies and Research.
- George W. Dunbar, Jr.
-
George W. Dunbar, Jr.，2012年加入Capricor, Inc成为公司董事会成员、审计委员会成员和薪酬委员会成员。Dunbar先生目前是ISTO Technologies. Inc.（一家私人持有的生物技术公司）技术总裁兼首席执行官。他生拥有广泛的医疗保健和生命科学的经营经验，并曾担任过多个私人和公共生命科学公司的前任董事或首席执行官。2010年加入 ISTO之前，他曾担任 Arboretum Ventures（一家领先的医疗风险投资公司）合资伙伴。他曾在以下投资公司担任过董事会成员：Intellicyt（提供高通量筛选和分析辅助药物发现）、KFx Medica（医疗器械公司）董事会主席和Cervilenz，Inc。（一家医疗设备公司）执行主席。他是Accuri Cytometers （现在为 Becton Dickinson & Co，一家细胞分析和流式细胞仪公司）过去的董事兼执行主席。他还曾担任几个公开上市公司的首席执行官和/或董事，均在医疗保健行业。此前，他曾担任上市公司Aastrom Biosciences（一家开发治疗严重慢性心血管疾病药物的生物技术公司）董事长兼首席执行官；上市公司Stem Cells Inc. （前身为 Cyto Therapeutics，从事发展干细胞疗法的公司）董事长和首席执行官；上市公司Metra Biosystems（一个发现生物标志物的公司）董事长和首席执行官；上市公司DepoTech（一家生物技术公司）董事自；上市公司LJL Biosystems（为生命科学行业提供药物发现的自动化系统供应商）董事长；以及上市公司Quidel Corporation（诊断测试解决方案开发和营销公司）董事长。他还曾在几家风险投资集团工作，在几个私人的生命科学公司担任顾问、董事或首席执行官，包括Quantum Dot，一个Versant Ventures / MPM资本公司；Targesome，Alloy Ventures/CHL医疗合作伙伴公司；以及Epic Therapeutics，一个MPM Capital/Proques投资公司。他还担任Ares-Serono（ 现为 Merck- Serono）和Amersham International（现为 GE Healthcare）高级领导职务。Dunbar先生从奥本大学获得电气工程学士学位，后来又获得了工商管理硕士学位。他目前担任哈勃商业学院MBA顾问委员会成员，和为范德堡大学技术转移和商业化中心担任顾问。
George W. Dunbar, Jr. joined the Capricor, Inc. Board of Directors in 2012 and is a member of the Company’s Audit Committee and Compensation Committee. Mr. Dunbar is currently President and Chief Executive Officer of ISTO Biologics, a privately-held orthobiologics company backed by Thompson Street Capital Partners. Mr. Dunbar has extensive healthcare and life sciences operating experience and has served as a director or CEO with private and public life science companies in Diagnostics, Specialty Pharma, Cell Therapy, and Biologics, two as CEO, where he led initial public offerings. Prior to joining ISTO, commencing in 2010 Mr. Dunbar served as a Venture Partner with Arboretum Ventures, a leading healthcare venture capital firm. Mr. Dunbar is currently a board member of Progenitor Life Sciences, a private next generation stem cell and immunotherapy development company. He has served as a board member for the following portfolio companies: IntelliCyt, a provider of high throughput screening and analytic tools, KFx Medical, an orthopedic medical device company as chair, and CerviLenz, Inc., a women’s health medical device company (as executive chair). He was a past director and executive chair of Accuri Cytometers (now Becton Dickinson & Co.), a cell analysis and flow cytometer company. Mr. Dunbar attended Auburn University where he graduated with a Bachelor of Science degree in Electrical Engineering and later received his M.B.A. He currently serves on the Harbert College of Business M.B.A. Advisory Board and is an advisor to Vanderbilt University’s Center for Technology Transfer and Commercialization. - George W. Dunbar, Jr.，2012年加入Capricor, Inc成为公司董事会成员、审计委员会成员和薪酬委员会成员。Dunbar先生目前是ISTO Technologies. Inc.（一家私人持有的生物技术公司）技术总裁兼首席执行官。他生拥有广泛的医疗保健和生命科学的经营经验，并曾担任过多个私人和公共生命科学公司的前任董事或首席执行官。2010年加入 ISTO之前，他曾担任 Arboretum Ventures（一家领先的医疗风险投资公司）合资伙伴。他曾在以下投资公司担任过董事会成员：Intellicyt（提供高通量筛选和分析辅助药物发现）、KFx Medica（医疗器械公司）董事会主席和Cervilenz，Inc。（一家医疗设备公司）执行主席。他是Accuri Cytometers （现在为 Becton Dickinson & Co，一家细胞分析和流式细胞仪公司）过去的董事兼执行主席。他还曾担任几个公开上市公司的首席执行官和/或董事，均在医疗保健行业。此前，他曾担任上市公司Aastrom Biosciences（一家开发治疗严重慢性心血管疾病药物的生物技术公司）董事长兼首席执行官；上市公司Stem Cells Inc. （前身为 Cyto Therapeutics，从事发展干细胞疗法的公司）董事长和首席执行官；上市公司Metra Biosystems（一个发现生物标志物的公司）董事长和首席执行官；上市公司DepoTech（一家生物技术公司）董事自；上市公司LJL Biosystems（为生命科学行业提供药物发现的自动化系统供应商）董事长；以及上市公司Quidel Corporation（诊断测试解决方案开发和营销公司）董事长。他还曾在几家风险投资集团工作，在几个私人的生命科学公司担任顾问、董事或首席执行官，包括Quantum Dot，一个Versant Ventures / MPM资本公司；Targesome，Alloy Ventures/CHL医疗合作伙伴公司；以及Epic Therapeutics，一个MPM Capital/Proques投资公司。他还担任Ares-Serono（ 现为 Merck- Serono）和Amersham International（现为 GE Healthcare）高级领导职务。Dunbar先生从奥本大学获得电气工程学士学位，后来又获得了工商管理硕士学位。他目前担任哈勃商业学院MBA顾问委员会成员，和为范德堡大学技术转移和商业化中心担任顾问。
- George W. Dunbar, Jr. joined the Capricor, Inc. Board of Directors in 2012 and is a member of the Company’s Audit Committee and Compensation Committee. Mr. Dunbar is currently President and Chief Executive Officer of ISTO Biologics, a privately-held orthobiologics company backed by Thompson Street Capital Partners. Mr. Dunbar has extensive healthcare and life sciences operating experience and has served as a director or CEO with private and public life science companies in Diagnostics, Specialty Pharma, Cell Therapy, and Biologics, two as CEO, where he led initial public offerings. Prior to joining ISTO, commencing in 2010 Mr. Dunbar served as a Venture Partner with Arboretum Ventures, a leading healthcare venture capital firm. Mr. Dunbar is currently a board member of Progenitor Life Sciences, a private next generation stem cell and immunotherapy development company. He has served as a board member for the following portfolio companies: IntelliCyt, a provider of high throughput screening and analytic tools, KFx Medical, an orthopedic medical device company as chair, and CerviLenz, Inc., a women’s health medical device company (as executive chair). He was a past director and executive chair of Accuri Cytometers (now Becton Dickinson & Co.), a cell analysis and flow cytometer company. Mr. Dunbar attended Auburn University where he graduated with a Bachelor of Science degree in Electrical Engineering and later received his M.B.A. He currently serves on the Harbert College of Business M.B.A. Advisory Board and is an advisor to Vanderbilt University’s Center for Technology Transfer and Commercialization.
- Earl M. Collier, Jr.
-
Earl M. Collier, Jr.，2011年加入Capricor, Inc董事会，是公司提名委员会及治理委员会成员。从2010年到2014年，他担任480 Biomedical（一家医疗设备公司，开发的产品用于外周动脉疾病的治疗）首席执行官和Arsenal Medical, Inc.（一家医疗设备公司）执行主席。Collier先生曾担任Genzyme Corporation（一家生物技术公司，2011年被Sanofi 以201亿美元收购）执行副总裁。他在GenzymeCorporation任职期间，负责建设经营生物外科事务和监督公司肿瘤、多发性硬化症和其他免疫系统疾病的进展。他领导了Genzyme一些重大收购工作和MG Biotherapeutics（Genzyme与Medtronic Inc的合资公司，专注于心肌细胞治疗）的成立。他还担任Vitas Healthcare（一家临终关怀机构，是位于华盛顿的法律公司Hogan and Hartson的合作伙伴）总裁和美国健康与人类服务部卫生保健财政管理局（现称CMS）副局长。他是牛顿韦尔斯利医院董事会主席、医疗系统的合作伙伴董事会成员和合作医疗创新顾问委员会主席。从2006年到2009年，Collier先生担任上市公司Decode Genetics Inc. （即DGI Resolution, Inc，是一家生物制药公司）董事长。他目前担任Tesaro, Inc.（一个公开上市的生物制药公司）董事会成员，和Transmedics（私人医疗器械公司）董事会成员。他在耶鲁大学获得了文学学士学位，在弗吉尼亚大学获得了法学学位。
Earl M. Collier, Jr. joined the Capricor, Inc. Board of Directors in 2011 and is a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. From 2010 - 2014 he served as the Chief Executive Officer of 480 Biomedical, a medical device company developing products used in the treatment of peripheral artery disease, and the executive chairman of Arsenal Medical, Inc., a medical device company. Mr. Collier was formerly Executive Vice President at Genzyme Corporation, a biotechnology company acquired by Sanofi for $20.1 billion in 2011. Mr. Collier also served as President of Vitas Healthcare, a hospice provider, as a partner at the Washington, DC-based law firm of Hogan and Hartson and as Deputy Administrator of the Health Care Finance Administration now CMS in the U.S. Department of Health & Human Services. He is Chairman of the Board of Trustees of the Newton-Wellesley Hospital, serves on the board of Partners HealthCare System and as Chair of the Innovation Advisory Board of Partners HealthCare. From 2006 to 2009 Mr. Collier served as a director of publicly-traded Decode Genetics Inc. (DGI Resolution, Inc.), a biopharmaceutical company, and he currently serves on the board of directors of Tesaro, Inc., a publicly-traded biopharmaceutical company and GenSight, a gene therapy company in Paris that trades on the French Euronext exchange. Mr. Collier earned a Bachelor of Arts degree at Yale University and received a law degree from the University of Virginia Law School. - Earl M. Collier, Jr.，2011年加入Capricor, Inc董事会，是公司提名委员会及治理委员会成员。从2010年到2014年，他担任480 Biomedical（一家医疗设备公司，开发的产品用于外周动脉疾病的治疗）首席执行官和Arsenal Medical, Inc.（一家医疗设备公司）执行主席。Collier先生曾担任Genzyme Corporation（一家生物技术公司，2011年被Sanofi 以201亿美元收购）执行副总裁。他在GenzymeCorporation任职期间，负责建设经营生物外科事务和监督公司肿瘤、多发性硬化症和其他免疫系统疾病的进展。他领导了Genzyme一些重大收购工作和MG Biotherapeutics（Genzyme与Medtronic Inc的合资公司，专注于心肌细胞治疗）的成立。他还担任Vitas Healthcare（一家临终关怀机构，是位于华盛顿的法律公司Hogan and Hartson的合作伙伴）总裁和美国健康与人类服务部卫生保健财政管理局（现称CMS）副局长。他是牛顿韦尔斯利医院董事会主席、医疗系统的合作伙伴董事会成员和合作医疗创新顾问委员会主席。从2006年到2009年，Collier先生担任上市公司Decode Genetics Inc. （即DGI Resolution, Inc，是一家生物制药公司）董事长。他目前担任Tesaro, Inc.（一个公开上市的生物制药公司）董事会成员，和Transmedics（私人医疗器械公司）董事会成员。他在耶鲁大学获得了文学学士学位，在弗吉尼亚大学获得了法学学位。
- Earl M. Collier, Jr. joined the Capricor, Inc. Board of Directors in 2011 and is a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. From 2010 - 2014 he served as the Chief Executive Officer of 480 Biomedical, a medical device company developing products used in the treatment of peripheral artery disease, and the executive chairman of Arsenal Medical, Inc., a medical device company. Mr. Collier was formerly Executive Vice President at Genzyme Corporation, a biotechnology company acquired by Sanofi for $20.1 billion in 2011. Mr. Collier also served as President of Vitas Healthcare, a hospice provider, as a partner at the Washington, DC-based law firm of Hogan and Hartson and as Deputy Administrator of the Health Care Finance Administration now CMS in the U.S. Department of Health & Human Services. He is Chairman of the Board of Trustees of the Newton-Wellesley Hospital, serves on the board of Partners HealthCare System and as Chair of the Innovation Advisory Board of Partners HealthCare. From 2006 to 2009 Mr. Collier served as a director of publicly-traded Decode Genetics Inc. (DGI Resolution, Inc.), a biopharmaceutical company, and he currently serves on the board of directors of Tesaro, Inc., a publicly-traded biopharmaceutical company and GenSight, a gene therapy company in Paris that trades on the French Euronext exchange. Mr. Collier earned a Bachelor of Arts degree at Yale University and received a law degree from the University of Virginia Law School.
- Joshua A. Kazam
-
Joshua A. Kazam，本公司的创始人之一，自2009年6月本公司成立之时起，担任董事。2009年6月，他联合创办咨询公司Two River Consulting, LLC.2005年10月起，他还担任Riverbank Capital Securities的主管、董事，这是FINRA的会员经纪交易商。2002-2004，他担任Orion Biomedical Fund的投资管理总监，这是专注于生物技术投资的私募股权基金。他获得了Wharton School of the University of Pennsylvania的创业管理学位。
Joshua A. Kazam served as Nile Therapeutics, Inc.’s non-employee President and Chief Executive Officer from June 2009 through August 2012 and has been serving as a director of the Company since its inception in August 2005. In June 2009 Mr. Kazam co-founded Two River Consulting, LLC, a consulting firm. He has also served as an officer and director of Riverbank Capital Securities, Inc., a FINRA member broker dealer, since October 2005. From 2002 to 2004 Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a private equity fund focused on biotechnology investments. From its inception in August 2005 until September 2010 Mr. Kazam also co-founded and served as a director of Arno Therapeutics, Inc., a publicly-held, New Jersey-based biopharmaceutical company focused on the treatment of cancer patients. Mr. Kazam is also a founder and director of Kite Pharma Inc., a publicly-traded biotechnology company, and serves as a director of Vetprime, Inc., a privately-held company and Hubble Contacts, a privately-held company. Mr. Kazam received his degree in Entrepreneurial Management from the Wharton School of the University of Pennsylvania. - Joshua A. Kazam，本公司的创始人之一，自2009年6月本公司成立之时起，担任董事。2009年6月，他联合创办咨询公司Two River Consulting, LLC.2005年10月起，他还担任Riverbank Capital Securities的主管、董事，这是FINRA的会员经纪交易商。2002-2004，他担任Orion Biomedical Fund的投资管理总监，这是专注于生物技术投资的私募股权基金。他获得了Wharton School of the University of Pennsylvania的创业管理学位。
- Joshua A. Kazam served as Nile Therapeutics, Inc.’s non-employee President and Chief Executive Officer from June 2009 through August 2012 and has been serving as a director of the Company since its inception in August 2005. In June 2009 Mr. Kazam co-founded Two River Consulting, LLC, a consulting firm. He has also served as an officer and director of Riverbank Capital Securities, Inc., a FINRA member broker dealer, since October 2005. From 2002 to 2004 Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a private equity fund focused on biotechnology investments. From its inception in August 2005 until September 2010 Mr. Kazam also co-founded and served as a director of Arno Therapeutics, Inc., a publicly-held, New Jersey-based biopharmaceutical company focused on the treatment of cancer patients. Mr. Kazam is also a founder and director of Kite Pharma Inc., a publicly-traded biotechnology company, and serves as a director of Vetprime, Inc., a privately-held company and Hubble Contacts, a privately-held company. Mr. Kazam received his degree in Entrepreneurial Management from the Wharton School of the University of Pennsylvania.
- Frank Litvack
-
Frank Litvack是FACC的医学博士。Litvack博士目前担任我们的执行董事长，是我们薪酬委员会的成员。Litvack博士是加拿大人。他在蒙特利尔McGill University完成医学院和住院医师实习，在洛杉矶Cedars-Sinai Medical Center完成心血管研究实习，在那里他随后成为the Cardiovascular Intervention Center的联合主管和加州大学洛杉矶分校（UCLA）的医学教授。在那里他领导突出的临床和研究项目（以其在转化医学中卓越的创新，护理和领导地位而闻名）。他由董事会认证（在内科，心血管疾病和介入性心脏病学）。他发表了一百多篇研究论文和章节，是几个奖项的接收者，包括American Heart Association Young Investigator Award（美国心脏病协会年轻调查员奖），the Leon Goldman Medical Excellence Award（莱昂高盛医学卓越奖）（在生物医学光学领域的贡献）和the United States Space Technology and Space Foundation Hall of Fame（美国空间技术和空间基础名人堂）（准分子激光的开创性工作）。他于2000年离开全职实践和学术知识，专注于企业活动。他创办和运营数家医疗企业，担任董事长和/或首席执行官，包括Progressive Angioplasty Systems Inc.（医疗设备公司，在1998年被United States Surgical Corp.收购）；Savacor, Inc.（医疗器械公司，在2005年被St. Jude Medical收购）；Conor Medsystems, Inc.（上市的医疗器械公司，在2007年被Johnson & Johnson收购）和其他几家企业；以及Entourage Medical Technologies Inc.（医疗设备公司，目前在发展）。他目前服务于几个早期医疗公司的董事会，是上市的Nile Therapeutics, Inc.的前任董事（从2009年到2012年）。他加入Capricor, Inc.的董事会，2012年担任执行主席。他目前是Pura Vida Investment, LLC（医疗对冲基金）的普通合伙人，并担任Cardiovascular Research Foundation（非盈利研究和教育实体）董事会的董事。
Frank Litvack, M.D. is currently serving as our Executive Chairman and as a member of our Compensation Committee and Nominating and Corporate Governance Committee. Dr. Litvack is a native of Canada. He completed medical school and residency at McGill University in Montreal and a Cardiovascular Fellowship at Cedars-Sinai Medical Center in Los Angeles, where he subsequently became co-director of the Cardiovascular Intervention Center and Professor of Medicine at UCLA. There he led a prominent clinical and research program known for its excellence in innovation, care and leadership in Translational Medicine. Dr. Litvack was Board certified in Internal Medicine, Cardiovascular Diseases and Interventional Cardiology. He has published more than one hundred research articles and chapters and is the recipient of several awards, including an American Heart Association Young Investigator Award, the Leon Goldman Medical Excellence Award for contributions to the field of biomedical optics and the United States Space Technology and Space Foundation Hall of Fame for pioneering work with the excimer laser. Dr. Litvack left full time practice and academics in 2000 to concentrate on entrepreneurial activities. Dr. Litvack has founded and operated several healthcare ventures, both as chairman and/or chief executive officer, including Progressive Angioplasty Systems Inc., a medical device company that was acquired by United States Surgical Corp. in 1998; Savacor, Inc., a medical device company that was acquired by St. Jude Medical in 2005; Conor Medsystems, Inc., a publicly traded medical device company that was acquired by Johnson & Johnson in 2007; Entourage Medical Technologies Inc., a medical device company currently in development; and several others. He presently sits on the boards of several early-stage healthcare companies. Dr. Litvack was a former director of publicly traded Nile Therapeutics, Inc. from 2009 - 2012. Dr. Litvack joined the Board of Capricor, Inc. as Executive Chairman in 2012. Dr. Litvack is currently a General Partner in Pura Vida Investment, LLC, a healthcare hedge fund, and is serving as a Director on the Board of Cardiovascular Research Foundation, a non-profit research and education entity. - Frank Litvack是FACC的医学博士。Litvack博士目前担任我们的执行董事长，是我们薪酬委员会的成员。Litvack博士是加拿大人。他在蒙特利尔McGill University完成医学院和住院医师实习，在洛杉矶Cedars-Sinai Medical Center完成心血管研究实习，在那里他随后成为the Cardiovascular Intervention Center的联合主管和加州大学洛杉矶分校（UCLA）的医学教授。在那里他领导突出的临床和研究项目（以其在转化医学中卓越的创新，护理和领导地位而闻名）。他由董事会认证（在内科，心血管疾病和介入性心脏病学）。他发表了一百多篇研究论文和章节，是几个奖项的接收者，包括American Heart Association Young Investigator Award（美国心脏病协会年轻调查员奖），the Leon Goldman Medical Excellence Award（莱昂高盛医学卓越奖）（在生物医学光学领域的贡献）和the United States Space Technology and Space Foundation Hall of Fame（美国空间技术和空间基础名人堂）（准分子激光的开创性工作）。他于2000年离开全职实践和学术知识，专注于企业活动。他创办和运营数家医疗企业，担任董事长和/或首席执行官，包括Progressive Angioplasty Systems Inc.（医疗设备公司，在1998年被United States Surgical Corp.收购）；Savacor, Inc.（医疗器械公司，在2005年被St. Jude Medical收购）；Conor Medsystems, Inc.（上市的医疗器械公司，在2007年被Johnson & Johnson收购）和其他几家企业；以及Entourage Medical Technologies Inc.（医疗设备公司，目前在发展）。他目前服务于几个早期医疗公司的董事会，是上市的Nile Therapeutics, Inc.的前任董事（从2009年到2012年）。他加入Capricor, Inc.的董事会，2012年担任执行主席。他目前是Pura Vida Investment, LLC（医疗对冲基金）的普通合伙人，并担任Cardiovascular Research Foundation（非盈利研究和教育实体）董事会的董事。
- Frank Litvack, M.D. is currently serving as our Executive Chairman and as a member of our Compensation Committee and Nominating and Corporate Governance Committee. Dr. Litvack is a native of Canada. He completed medical school and residency at McGill University in Montreal and a Cardiovascular Fellowship at Cedars-Sinai Medical Center in Los Angeles, where he subsequently became co-director of the Cardiovascular Intervention Center and Professor of Medicine at UCLA. There he led a prominent clinical and research program known for its excellence in innovation, care and leadership in Translational Medicine. Dr. Litvack was Board certified in Internal Medicine, Cardiovascular Diseases and Interventional Cardiology. He has published more than one hundred research articles and chapters and is the recipient of several awards, including an American Heart Association Young Investigator Award, the Leon Goldman Medical Excellence Award for contributions to the field of biomedical optics and the United States Space Technology and Space Foundation Hall of Fame for pioneering work with the excimer laser. Dr. Litvack left full time practice and academics in 2000 to concentrate on entrepreneurial activities. Dr. Litvack has founded and operated several healthcare ventures, both as chairman and/or chief executive officer, including Progressive Angioplasty Systems Inc., a medical device company that was acquired by United States Surgical Corp. in 1998; Savacor, Inc., a medical device company that was acquired by St. Jude Medical in 2005; Conor Medsystems, Inc., a publicly traded medical device company that was acquired by Johnson & Johnson in 2007; Entourage Medical Technologies Inc., a medical device company currently in development; and several others. He presently sits on the boards of several early-stage healthcare companies. Dr. Litvack was a former director of publicly traded Nile Therapeutics, Inc. from 2009 - 2012. Dr. Litvack joined the Board of Capricor, Inc. as Executive Chairman in 2012. Dr. Litvack is currently a General Partner in Pura Vida Investment, LLC, a healthcare hedge fund, and is serving as a Director on the Board of Cardiovascular Research Foundation, a non-profit research and education entity.
高管简历
中英对照 | 中文 | 英文- Linda Marban
Linda Marban，博士，目前担任Capricor Therapeutics, Inc.的全资子公司Capricor, Inc首席执行官。她于2005年联合创立Capricor, Inc，并于2010年成为首席执行官。她将她的商业经验与研究背景结合起来领导Capricor，为其心脏治疗新疗法创造一个商业化路径。她是Capricor的基础即知识产权组合许可协议谈判的首席代表。在她担任首席执行官期间，Capricor, Inc担保美元的非稀释赠款和贷款奖励达到将近2700万美元，这些赠款和贷款奖励用来支持公司的研发项目和包括cap-1002产品在内的临床试验。她丰富的心脏空间知识，特别让她为公司的发展和成长提供独特的方向。从2003年到2009年，Marban 博士在Excigen，Inc.（一家生物技术初创公司）工作，负责业务开发、操作和临床前研究，并监督与Genzyme Corp达成的联合开发协议中基因治疗产品的开发。在Excigen工作期间，她也与Medtronic Corp.达成了共同开发与代理从属经营许可，利用Excigen的技术并监督执行此项任务的实验室的建立。她的职业生涯开始于学术科学研究，首先在克利夫兰医学中心工作，研究心肌的生物物理特性。当她搬到了约翰霍普金斯大学后这项工作继续进行。在约翰霍普金斯大学，她晋升为儿科研究助理教授级别，继续她对心衰收缩功能障碍的机制的研究。她在霍普金斯大学的任期从2000年持续到了2003年。Marban博士从凯斯西储大学获得了心脏生理学博士学位。
Linda Marban, Ph.D. is currently serving as Capricor Therapeutics, Inc.'s Chief Executive Officer. Co-founder of Capricor, Inc., Capricor Therapeutics, Inc.'s wholly-owned subsidiary, Dr. Marbán has been with Capricor, Inc. since 2005 and became its Chief Executive Officer in 2010. Dr. Marbán was the lead negotiator in procuring the license agreements that are the foundation of Capricor, Inc.'s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor, Inc. secured over $30.0 million in non-dilutive grants and a loan award which funds Capricor, Inc.'s research and development programs and clinical trials involving its CAP-1002 product. Dr. Marbán's deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company's development and growth. From 2003 to 2009 Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen's technology and supervised the building of a lab in which the work was to be performed. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University "JHU". While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.- Linda Marban，博士，目前担任Capricor Therapeutics, Inc.的全资子公司Capricor, Inc首席执行官。她于2005年联合创立Capricor, Inc，并于2010年成为首席执行官。她将她的商业经验与研究背景结合起来领导Capricor，为其心脏治疗新疗法创造一个商业化路径。她是Capricor的基础即知识产权组合许可协议谈判的首席代表。在她担任首席执行官期间，Capricor, Inc担保美元的非稀释赠款和贷款奖励达到将近2700万美元，这些赠款和贷款奖励用来支持公司的研发项目和包括cap-1002产品在内的临床试验。她丰富的心脏空间知识，特别让她为公司的发展和成长提供独特的方向。从2003年到2009年，Marban 博士在Excigen，Inc.（一家生物技术初创公司）工作，负责业务开发、操作和临床前研究，并监督与Genzyme Corp达成的联合开发协议中基因治疗产品的开发。在Excigen工作期间，她也与Medtronic Corp.达成了共同开发与代理从属经营许可，利用Excigen的技术并监督执行此项任务的实验室的建立。她的职业生涯开始于学术科学研究，首先在克利夫兰医学中心工作，研究心肌的生物物理特性。当她搬到了约翰霍普金斯大学后这项工作继续进行。在约翰霍普金斯大学，她晋升为儿科研究助理教授级别，继续她对心衰收缩功能障碍的机制的研究。她在霍普金斯大学的任期从2000年持续到了2003年。Marban博士从凯斯西储大学获得了心脏生理学博士学位。
- Linda Marban, Ph.D. is currently serving as Capricor Therapeutics, Inc.'s Chief Executive Officer. Co-founder of Capricor, Inc., Capricor Therapeutics, Inc.'s wholly-owned subsidiary, Dr. Marbán has been with Capricor, Inc. since 2005 and became its Chief Executive Officer in 2010. Dr. Marbán was the lead negotiator in procuring the license agreements that are the foundation of Capricor, Inc.'s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor, Inc. secured over $30.0 million in non-dilutive grants and a loan award which funds Capricor, Inc.'s research and development programs and clinical trials involving its CAP-1002 product. Dr. Marbán's deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company's development and growth. From 2003 to 2009 Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen's technology and supervised the building of a lab in which the work was to be performed. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University "JHU". While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.
- Anthony Bergmann
Anthony Bergmann，工商管理硕士。加入 Capricor之前，Bergmann先生拥有会计、财务和从初创企业到中等规模的企业运营管理的经验。最近他任职于商业管理公司Gettleson, Witzer and O&'Connor（位于加利福尼亚州贝弗利山），在那里他专注于几个全球收入超过10亿美元电影发行制作工作室的会计和金融。该公司的客户包括基金会、信托公司和整个娱乐行业的独立演员、作家、制片人和导演。而他在此公司负责预算、税收预测和资产管理。在他职业生涯的早期，Bergmann先生担任过各个行业的财务职位。他于2011年加入Capricor，并担任财务总监直到2013年11月。Capricor与Nile Therapeutics, Inc合并后，他还担任财务副总裁和企业会计。他曾协助公司的A-3系列600万美元优先股发行，帮助公司成功组织1980万美元的加利福尼亚再生医学研究所预算提案，并协调公司的反向收购和私募，公司在2015年初收益超过1700万美元。他在发展企业战略、财务战略的选择和执行战略计划方面有丰富的经验。现在他负责公司的财务经验、会计和人力资源职能。他毕业于普罗维登斯大学管理学专业，辅修金融。他还拥有南加州大学马歇尔商学院工商管理硕士学位。他正积极参与整个洛矶地区的各种风险投资和创业协会。
Anthony Bergmann, M.B.A. Prior to joining Capricor, Mr. Bergmann had experience in accounting, finance and operations management of companies ranging in size from start-ups to mid-size companies. Most recently he was with the business management firm, Gettleson, Witzer and O’Connor, in Beverly Hills, California, where he focused on accounting and finance for several production studios generating motion picture releases and worldwide revenue that exceeded $1 billion. The firm’s clients included foundations, trusts, and independent actors, writers, producers and directors across the entertainment industry. While at the firm, he focused on budgeting, tax forecasting and asset management. Earlier in his career, Mr. Bergmann served in financial positions in various industries. Mr. Bergmann joined Capricor in 2011 and served as the Director of Finance until November 2013. After the merger with Nile Therapeutics, Inc., he was made the Vice President of Finance. He also serves as the Company’s corporate treasurer. Mr. Bergmann assisted with the Company’s Series A-3 $6.0 million Preferred Stock offering, helped structure the Company’s successful $19.8 million budget proposal to the California Institute for Regenerative Medicine and coordinated the Company’s reverse merger and recent financings yielding over $30 million in 2015 and 2016. He has experience in developing corporate and financial strategy alternatives and executing on strategic plans Mr. Bergmann manages the Company’s finance, accounting and human resource functions. Mr. Bergmann graduated from Providence College with a Bachelor of Science degree in Management, and a minor in Finance. He has an M.B.A. from the University of Southern California’s Marshall School of Business. He is actively involved in various venture capital and entrepreneurial associations throughout the Los Angeles area.- Anthony Bergmann，工商管理硕士。加入 Capricor之前，Bergmann先生拥有会计、财务和从初创企业到中等规模的企业运营管理的经验。最近他任职于商业管理公司Gettleson, Witzer and O&'Connor（位于加利福尼亚州贝弗利山），在那里他专注于几个全球收入超过10亿美元电影发行制作工作室的会计和金融。该公司的客户包括基金会、信托公司和整个娱乐行业的独立演员、作家、制片人和导演。而他在此公司负责预算、税收预测和资产管理。在他职业生涯的早期，Bergmann先生担任过各个行业的财务职位。他于2011年加入Capricor，并担任财务总监直到2013年11月。Capricor与Nile Therapeutics, Inc合并后，他还担任财务副总裁和企业会计。他曾协助公司的A-3系列600万美元优先股发行，帮助公司成功组织1980万美元的加利福尼亚再生医学研究所预算提案，并协调公司的反向收购和私募，公司在2015年初收益超过1700万美元。他在发展企业战略、财务战略的选择和执行战略计划方面有丰富的经验。现在他负责公司的财务经验、会计和人力资源职能。他毕业于普罗维登斯大学管理学专业，辅修金融。他还拥有南加州大学马歇尔商学院工商管理硕士学位。他正积极参与整个洛矶地区的各种风险投资和创业协会。
- Anthony Bergmann, M.B.A. Prior to joining Capricor, Mr. Bergmann had experience in accounting, finance and operations management of companies ranging in size from start-ups to mid-size companies. Most recently he was with the business management firm, Gettleson, Witzer and O’Connor, in Beverly Hills, California, where he focused on accounting and finance for several production studios generating motion picture releases and worldwide revenue that exceeded $1 billion. The firm’s clients included foundations, trusts, and independent actors, writers, producers and directors across the entertainment industry. While at the firm, he focused on budgeting, tax forecasting and asset management. Earlier in his career, Mr. Bergmann served in financial positions in various industries. Mr. Bergmann joined Capricor in 2011 and served as the Director of Finance until November 2013. After the merger with Nile Therapeutics, Inc., he was made the Vice President of Finance. He also serves as the Company’s corporate treasurer. Mr. Bergmann assisted with the Company’s Series A-3 $6.0 million Preferred Stock offering, helped structure the Company’s successful $19.8 million budget proposal to the California Institute for Regenerative Medicine and coordinated the Company’s reverse merger and recent financings yielding over $30 million in 2015 and 2016. He has experience in developing corporate and financial strategy alternatives and executing on strategic plans Mr. Bergmann manages the Company’s finance, accounting and human resource functions. Mr. Bergmann graduated from Providence College with a Bachelor of Science degree in Management, and a minor in Finance. He has an M.B.A. from the University of Southern California’s Marshall School of Business. He is actively involved in various venture capital and entrepreneurial associations throughout the Los Angeles area.
- Karen G. Krasney
Karen G. Krasney，法学博士。目前担任公司执行副总裁、秘书和总法律顾问。她的职业生涯跨越了35多年，为众多企业和私营企业担任各种行业的总顾问。她广泛的背景和丰富的经验集中在国内外企业和商业法律以及诉讼。90年代中期以来，Krasney女士主要从事医疗技术领域，代表几个医疗技术公司开发用于治疗心血管疾病的产品。2002年开始她担任Biosensors International Group Ltd（一个跨国医疗器械公司，开发、制造和销售用于心脏病治疗的医疗设备）法律顾问。2006年，她开始担任Biosensors 总法律顾问和执行副总裁，并一直工作到2010年。她在Biosensors 任职期间，在其他方面，以她为首的法律团队促进了公司在新加坡的成功上市，负责谈判和记录公司全球所有的协议，包括本公司及国际临床试验所需的主要医疗设备公司和协议许可协议。2011年起，她开始为Capricor提供法律服务，2012年她成为公司执行副总裁兼总法律顾问。她还担任心血管研究基金会（一个非营利性科研和教育机构）董事长。她从加利福尼亚大学洛杉矶分校获得了文学学士学位，并从南加州大学获得法学博士学位。
Karen G. Krasney, J.D. is currently serving as our Executive Vice President, Secretary and General Counsel. Ms. Krasney’s career spans over 35 years serving as general counsel for numerous corporations and private companies engaged in a wide variety of industries. Her extensive background and vast experience has been focused on domestic and international corporate and business law, as well as litigation. Ms. Krasney has been involved in the medical technology arena since the mid 1990’s, representing several medical technology companies developing products for the treatment of cardiovascular disease. Commencing in 2002 Ms. Krasney served as legal counsel of Biosensors International Group Ltd., a multinational medical device company that develops, manufactures and sells medical devices for cardiology applications. In 2006 she accepted the position of General Counsel and Executive Vice President of Biosensors and served in that capacity until 2010. During her tenure at Biosensors, among other things, Ms. Krasney headed the legal team that facilitated the company’s successful initial public offering in Singapore and was responsible for negotiating and documenting all agreements for the company worldwide, including licensing agreements with major medical device companies and agreements required for the company’s international clinical trials. Ms. Krasney has been providing legal services to Capricor since 2011 and in 2012 joined Capricor as its Executive Vice President and General Counsel. Ms. Krasney also serves as a director on the Board of Cardiovascular Research Foundation, a non-profit research and education entity. Ms. Krasney received her Bachelor of Arts degree from the University of California, Los Angeles and her Juris Doctorate from the University of Southern California.- Karen G. Krasney，法学博士。目前担任公司执行副总裁、秘书和总法律顾问。她的职业生涯跨越了35多年，为众多企业和私营企业担任各种行业的总顾问。她广泛的背景和丰富的经验集中在国内外企业和商业法律以及诉讼。90年代中期以来，Krasney女士主要从事医疗技术领域，代表几个医疗技术公司开发用于治疗心血管疾病的产品。2002年开始她担任Biosensors International Group Ltd（一个跨国医疗器械公司，开发、制造和销售用于心脏病治疗的医疗设备）法律顾问。2006年，她开始担任Biosensors 总法律顾问和执行副总裁，并一直工作到2010年。她在Biosensors 任职期间，在其他方面，以她为首的法律团队促进了公司在新加坡的成功上市，负责谈判和记录公司全球所有的协议，包括本公司及国际临床试验所需的主要医疗设备公司和协议许可协议。2011年起，她开始为Capricor提供法律服务，2012年她成为公司执行副总裁兼总法律顾问。她还担任心血管研究基金会（一个非营利性科研和教育机构）董事长。她从加利福尼亚大学洛杉矶分校获得了文学学士学位，并从南加州大学获得法学博士学位。
- Karen G. Krasney, J.D. is currently serving as our Executive Vice President, Secretary and General Counsel. Ms. Krasney’s career spans over 35 years serving as general counsel for numerous corporations and private companies engaged in a wide variety of industries. Her extensive background and vast experience has been focused on domestic and international corporate and business law, as well as litigation. Ms. Krasney has been involved in the medical technology arena since the mid 1990’s, representing several medical technology companies developing products for the treatment of cardiovascular disease. Commencing in 2002 Ms. Krasney served as legal counsel of Biosensors International Group Ltd., a multinational medical device company that develops, manufactures and sells medical devices for cardiology applications. In 2006 she accepted the position of General Counsel and Executive Vice President of Biosensors and served in that capacity until 2010. During her tenure at Biosensors, among other things, Ms. Krasney headed the legal team that facilitated the company’s successful initial public offering in Singapore and was responsible for negotiating and documenting all agreements for the company worldwide, including licensing agreements with major medical device companies and agreements required for the company’s international clinical trials. Ms. Krasney has been providing legal services to Capricor since 2011 and in 2012 joined Capricor as its Executive Vice President and General Counsel. Ms. Krasney also serves as a director on the Board of Cardiovascular Research Foundation, a non-profit research and education entity. Ms. Krasney received her Bachelor of Arts degree from the University of California, Los Angeles and her Juris Doctorate from the University of Southern California.
- Rachel Smith
Rachel Smith，博士，目前担任我们的研发副总裁。Smith博士2008年加入 Capricor，是Capricor产品组合核心cardiospheretm技术的共同发明人。她还发表了开创性的概念验证论文，证明cardiosphere源干细胞在心脏疾病模型的临床应用。她的研究专长包括干细胞生物学、心脏生理学、电生理学以及细胞和组织工程领域。2012年她被任命为Capricor 研究和开发副总裁，负责开发公司的临床试验方案、管理其监管会和研究伙伴关系。在Eduardo Marban博士的指导下和惠特克基金会的奖学金和国家科学基金会研究生奖学金的支持下，Smith博士从约翰霍普金斯大学获得生物医学工程博士学位。她以优异的成绩从杜兰大学获得了生物医学工程学士学位。
Rachel Smith, Ph.D. is currently serving as our Vice President of Research and Development. Dr. Smith joined Capricor in 2008 and is a co-inventor of the CardiosphereTM technology that forms the core of Capricor’s product portfolio. She also published the seminal proof-of-concept paper demonstrating the clinical utility of the Cardiosphere-derived stem cells in models of heart disease. Her research expertise encompasses the areas of stem cell biology, cardiac physiology, electrophysiology, as well as cell and tissue engineering. In 2012 Dr. Smith was appointed Vice President of Research and Development of Capricor and is responsible for developing the company’s clinical trial protocols and managing its regulatory and research partner relationships. Dr. Smith obtained her Ph.D. in Biomedical Engineering from Johns Hopkins University under the advisement of Dr. Eduardo Marbán and with the support of a Whitaker Foundation Graduate Fellowship and a National Science Foundation Graduate Fellowship. She received her undergraduate degree in Biomedical Engineering, Magna Cum Laude, from Tulane University.- Rachel Smith，博士，目前担任我们的研发副总裁。Smith博士2008年加入 Capricor，是Capricor产品组合核心cardiospheretm技术的共同发明人。她还发表了开创性的概念验证论文，证明cardiosphere源干细胞在心脏疾病模型的临床应用。她的研究专长包括干细胞生物学、心脏生理学、电生理学以及细胞和组织工程领域。2012年她被任命为Capricor 研究和开发副总裁，负责开发公司的临床试验方案、管理其监管会和研究伙伴关系。在Eduardo Marban博士的指导下和惠特克基金会的奖学金和国家科学基金会研究生奖学金的支持下，Smith博士从约翰霍普金斯大学获得生物医学工程博士学位。她以优异的成绩从杜兰大学获得了生物医学工程学士学位。
- Rachel Smith, Ph.D. is currently serving as our Vice President of Research and Development. Dr. Smith joined Capricor in 2008 and is a co-inventor of the CardiosphereTM technology that forms the core of Capricor’s product portfolio. She also published the seminal proof-of-concept paper demonstrating the clinical utility of the Cardiosphere-derived stem cells in models of heart disease. Her research expertise encompasses the areas of stem cell biology, cardiac physiology, electrophysiology, as well as cell and tissue engineering. In 2012 Dr. Smith was appointed Vice President of Research and Development of Capricor and is responsible for developing the company’s clinical trial protocols and managing its regulatory and research partner relationships. Dr. Smith obtained her Ph.D. in Biomedical Engineering from Johns Hopkins University under the advisement of Dr. Eduardo Marbán and with the support of a Whitaker Foundation Graduate Fellowship and a National Science Foundation Graduate Fellowship. She received her undergraduate degree in Biomedical Engineering, Magna Cum Laude, from Tulane University.
- Leland Gershel
Leland Gershel，加入Capricor公司之前，他曾担任Tonix Pharmaceuticals Holding Corp.的首席财务官（2012年4月至2016年1月），以及其财务主管（从2012年11月到2016年1月）。2011年5月至2011年12月，他曾担任Madison Williams and Company的董事总经理兼高级分析师，在那里他曾负责专业制药和生物技术公司的股票研究。2010年4月至2010年10月，他曾担任Favus Institutional Research的高级分析师，在那里他曾负责向机构投资者发布各种医疗保健公司研究报告。2008年10月至2009年10月，他曾担任Apothecary Capital公司（医疗投资公司）的高级分析师。2004年11月至2008年9月，他曾担任Cowen and Company的股票研究分析师，最近担任副总裁，在那里他曾负责中小市值生物技术公司的股票研究。他持有Columbia University的医学博士学位、有机化学博士学位。他持有Dartmouth College的化学和亚洲研究学士学位（以优异成绩获得）。他是的SAHA/vorinostat（作为Zolinza 由Merck市场推广，是获得FDA批准的第一个组蛋白脱乙酰酶HDAC抑制剂）的专利发明家。
Leland Gershel, M.D., Ph.D. Prior to joining Capricor, Dr. Gershell served as the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. from April 2012 to January 2016 and as its Treasurer from November 2012 to January 2016. From May 2011 to December 2011 Dr. Gershell was Managing Director and Senior Analyst at Madison Williams and Company, where he was responsible for equity research coverage of specialty pharmaceutical and biotechnology companies. From April 2010 to October 2010 Dr. Gershell was Senior Analyst at Favus Institutional Research, where he was responsible for issuing research reports on a variety of healthcare companies to institutional investors. From October 2008 to October 2009 Dr. Gershell was Senior Analyst at Apothecary Capital, a healthcare investment firm. From November 2004 to September 2008 Dr. Gershell was an equity research analyst at Cowen and Company, most recently as Vice President, where he was responsible for the equity research coverage of small and middle capitalization biotechnology companies. Dr. Gershell earned his M.D. and Ph.D. in Organic Chemistry from Columbia University and his B.A. magna cum laude in Chemistry and Asian Studies from Dartmouth College. Dr. Gershell is an inventor on patents for SAHA/vorinostat, which is marketed by Merck as Zolinza® and is the first histone deacetylase HDAC inhibitor to receive FDA approval.- Leland Gershel，加入Capricor公司之前，他曾担任Tonix Pharmaceuticals Holding Corp.的首席财务官（2012年4月至2016年1月），以及其财务主管（从2012年11月到2016年1月）。2011年5月至2011年12月，他曾担任Madison Williams and Company的董事总经理兼高级分析师，在那里他曾负责专业制药和生物技术公司的股票研究。2010年4月至2010年10月，他曾担任Favus Institutional Research的高级分析师，在那里他曾负责向机构投资者发布各种医疗保健公司研究报告。2008年10月至2009年10月，他曾担任Apothecary Capital公司（医疗投资公司）的高级分析师。2004年11月至2008年9月，他曾担任Cowen and Company的股票研究分析师，最近担任副总裁，在那里他曾负责中小市值生物技术公司的股票研究。他持有Columbia University的医学博士学位、有机化学博士学位。他持有Dartmouth College的化学和亚洲研究学士学位（以优异成绩获得）。他是的SAHA/vorinostat（作为Zolinza 由Merck市场推广，是获得FDA批准的第一个组蛋白脱乙酰酶HDAC抑制剂）的专利发明家。
- Leland Gershel, M.D., Ph.D. Prior to joining Capricor, Dr. Gershell served as the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. from April 2012 to January 2016 and as its Treasurer from November 2012 to January 2016. From May 2011 to December 2011 Dr. Gershell was Managing Director and Senior Analyst at Madison Williams and Company, where he was responsible for equity research coverage of specialty pharmaceutical and biotechnology companies. From April 2010 to October 2010 Dr. Gershell was Senior Analyst at Favus Institutional Research, where he was responsible for issuing research reports on a variety of healthcare companies to institutional investors. From October 2008 to October 2009 Dr. Gershell was Senior Analyst at Apothecary Capital, a healthcare investment firm. From November 2004 to September 2008 Dr. Gershell was an equity research analyst at Cowen and Company, most recently as Vice President, where he was responsible for the equity research coverage of small and middle capitalization biotechnology companies. Dr. Gershell earned his M.D. and Ph.D. in Organic Chemistry from Columbia University and his B.A. magna cum laude in Chemistry and Asian Studies from Dartmouth College. Dr. Gershell is an inventor on patents for SAHA/vorinostat, which is marketed by Merck as Zolinza® and is the first histone deacetylase HDAC inhibitor to receive FDA approval.
- Deborah Ascheim
Deborah Ascheim，于2015年加入Capricor，目前担任我们的首席医疗官。她是心力衰竭心脏病专家，拥有重要经验，指导由美国国立卫生研究院和行业赞助商创建的国家和国际临床试验。她最近担任卫生政策和医学教授，也曾担任纽约西奈山伊坎医学院（the Icahn School of Medicine at Mount Sinai）的国际健康结果和创新研究中心（the International Center for Health Outcomes and Innovation Research）的临床试验中心的董事。任职Mount Sinai之前，她曾任教于哥伦比亚大学内科医生和外科医生学院（the College of Physicians & Surgeons at Columbia University）的医学和心脏病系。她曾在西奈山和哥伦比亚工作，期间她曾担任首席研究员、副首席科学家，负责许多高冲击强度心血管试验，包括美国国立卫生研究院支持心胸外科实验网络数据协调中心。她一直担任个国家卫生研究院支持的LVAD患者干细胞试验的主要研究者，以及NIH CTRIP，授权对心力衰竭的治疗中的靶向基因治疗进行评估。任职于内科医生和外科医生学院期间，她也曾担任主要研究者、网站首席研究员，负责许多制药、生物技术和医疗器械临床试验。1997年以来，她曾任职或主管多种美国国立卫生研究院和行业的临床试验委员会。她获得New York University School of medicine的医学博士学位，以及Wellesley College的学士学位。
Deborah Ascheim, M.D. joined Capricor in 2015 and is currently serving as our Chief Medical Officer. Dr. Ascheim, a heart failure cardiologist, has significant experience directing national and international clinical trials, funded by both the NIH and industry sponsors. She was most recently Professor of Health Policy and Medicine and was the director of the International Center for Health Outcomes and Innovation Research’s Clinical Trial Unit at the Icahn School of Medicine at Mount Sinai in New York. Prior to her tenure at Mount Sinai, Dr. Ascheim was on faculty in the Department of Medicine and division of Cardiology at the College of Physicians & Surgeons at Columbia University. While at Mount Sinai and Columbia, she served as either principal investigator or co-principal investigator for numerous high impact cardiovascular trials, including the NIH supported Cardiothoracic Surgical trials Network data coordinating center. She has been the principal investigator of an NIH supported trial of stem cells in LVAD patients, as well as an NIH CTRIP grant to evaluate targeted gene therapy for the treatment of heart failure. While at the College of Physicians & Surgeons, she also served as principal investigator or site principal investigator for a number of pharmaceutical, biotechnology and medical device clinical trials. Since 1997 she has served on or chaired a variety of clinical trial committees for both the National Institutes of Health and industry. Dr. Ascheim received her M.D. from New York University School of Medicine and a B.A. from Wellesley College.- Deborah Ascheim，于2015年加入Capricor，目前担任我们的首席医疗官。她是心力衰竭心脏病专家，拥有重要经验，指导由美国国立卫生研究院和行业赞助商创建的国家和国际临床试验。她最近担任卫生政策和医学教授，也曾担任纽约西奈山伊坎医学院（the Icahn School of Medicine at Mount Sinai）的国际健康结果和创新研究中心（the International Center for Health Outcomes and Innovation Research）的临床试验中心的董事。任职Mount Sinai之前，她曾任教于哥伦比亚大学内科医生和外科医生学院（the College of Physicians & Surgeons at Columbia University）的医学和心脏病系。她曾在西奈山和哥伦比亚工作，期间她曾担任首席研究员、副首席科学家，负责许多高冲击强度心血管试验，包括美国国立卫生研究院支持心胸外科实验网络数据协调中心。她一直担任个国家卫生研究院支持的LVAD患者干细胞试验的主要研究者，以及NIH CTRIP，授权对心力衰竭的治疗中的靶向基因治疗进行评估。任职于内科医生和外科医生学院期间，她也曾担任主要研究者、网站首席研究员，负责许多制药、生物技术和医疗器械临床试验。1997年以来，她曾任职或主管多种美国国立卫生研究院和行业的临床试验委员会。她获得New York University School of medicine的医学博士学位，以及Wellesley College的学士学位。
- Deborah Ascheim, M.D. joined Capricor in 2015 and is currently serving as our Chief Medical Officer. Dr. Ascheim, a heart failure cardiologist, has significant experience directing national and international clinical trials, funded by both the NIH and industry sponsors. She was most recently Professor of Health Policy and Medicine and was the director of the International Center for Health Outcomes and Innovation Research’s Clinical Trial Unit at the Icahn School of Medicine at Mount Sinai in New York. Prior to her tenure at Mount Sinai, Dr. Ascheim was on faculty in the Department of Medicine and division of Cardiology at the College of Physicians & Surgeons at Columbia University. While at Mount Sinai and Columbia, she served as either principal investigator or co-principal investigator for numerous high impact cardiovascular trials, including the NIH supported Cardiothoracic Surgical trials Network data coordinating center. She has been the principal investigator of an NIH supported trial of stem cells in LVAD patients, as well as an NIH CTRIP grant to evaluate targeted gene therapy for the treatment of heart failure. While at the College of Physicians & Surgeons, she also served as principal investigator or site principal investigator for a number of pharmaceutical, biotechnology and medical device clinical trials. Since 1997 she has served on or chaired a variety of clinical trial committees for both the National Institutes of Health and industry. Dr. Ascheim received her M.D. from New York University School of Medicine and a B.A. from Wellesley College.